Olema Pharmaceuticals Inc. (NASDAQ:OLMA) stock is trading lower on Monday, in reaction to data from Roche Holdings AG’s (OTC:RHHBY) phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. • Olema Pharmaceuticals stock is feeling bearish pressure. Why are OLMA shares down?The study did not meet its primary objective of a statistically significant improvement in progression-free survival versus letrozole plus palbociclib.The study showed a numerical improve ...